Satellos Bioscience (MSLE)
NASDAQ:MSLE
MSLE Stock Chart & Stats
$8.70
$0.00(0.00%)
At close: 4:00 PM EST
$8.70
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.53 - $13.39
Previous CloseN/A
VolumeN/A
Average Volume (3M)129.72K
Market Cap
$119.38M
Enterprise Value$41.10M
Total Cash (Recent Filing)$69.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 31, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding20,831,190
10 Day Avg. Volume192,609
30 Day Avg. Volume129,722
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-3.51
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.13K
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$21.52Price Target Upside147.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially lowers financial distress risk for a pre-revenue biotech. Without interest obligations or covenants, management has more flexibility to time equity raises, fund R&D, and pursue clinical milestones without near-term default risk, supporting runway management over the coming months.
Focused Therapeutic PipelineConcentrated expertise in skeletal muscle disorders and Duchenne muscular dystrophy provides clear strategic focus and potential competitive differentiation. A tight pipeline can concentrate R&D resources, accelerate program decisions, and make regulatory and payer engagement more efficient if clinical progress is achieved.
Recent FCF Improvement TrendObserved improvement in trailing-twelve-month free cash flow versus the prior year suggests management actions or milestone timing are reducing burn. If sustained, this trend can extend runway, lower near-term financing needs, and improve strategic optionality—important for a pre-revenue developer over the next several quarters.
Bears Say
Pre-revenue With Widening LossesLarge, increasing operating losses without commercial revenue mean the business depends entirely on financing and pipeline success for survival. Continued negative earnings deepen cumulative deficits and necessitate capital raises or partnerships, raising dilution and execution risk over the medium term.
Persistent Negative Free Cash FlowSustained negative free cash flow indicates the company is consuming capital to fund R&D rather than generating it. This persistent burn requires repeated external funding or asset sales, which can be dilutive, time-consuming, and may constrain investment in multiple programs simultaneously.
Negative ROE And Volatile EquityA deeply negative ROE and volatile shareholder equity signal poor capital efficiency and likely equity raises or accumulated losses. Such dynamics erode investor value, complicate future fundraising terms, and suggest management must demonstrate clear clinical progress to restore confidence and capital access.
Satellos Bioscience News
MSLE FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was $4.53 and its highest was $13.39 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is $119.38M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Aug 31, 2026 which is in 78 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on May 15, 2026. The company reported -$0.521 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.039.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.51.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 20,831,190 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -$0.521 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went down -2.232%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in MSLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.52 (147.30% Upside)
$21.52 (147.30% Upside)
Blogger Sentiment
Bullish
MSLE Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $180.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.16%
12-Months-Change
Fundamentals
Return on Equity
-51.42%
Trailing 12-Months
Asset Growth
69.55%
Trailing 12-Months
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
MSLE Stock 12 Month Forecast
Average Price Target
$21.52
▲(147.30% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Ownership Overview
6.66% Insiders
5.58% Mutual Funds
22.62% Other Institutional Investors
65.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---